Study	Total	Experi Mean	mental SD		Mean	Control SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
g = 3-4months											
Bachert (2016)	30	9.40	5.1000	30	18.60	5.0000	<del></del>	-9.20	[-11.76; -6.64]	4.1%	16.0%
Fixed effect model	30			30				-9.20	[-11.76; -6.64]	4.1%	-
Random effects model								-9.20	[-11.76; -6.64]		16.0%
Heterogeneity: not applicable											
g = 6-8months											
Bachert 2019 SINUS-24	143	10.89	4.8200	143	18.55	4.5500	<del>=</del> :	-7.66	[-8.75; -6.57]	22.6%	23.0%
Bachert 2019 SINUS-52 2wks	150	12.86	3.8700	150	18.42	3.6100		-5.56	[-6.41; -4.71]	37.2%	23.9%
Bachert 2019 SINUS-52 2wks-4wks	145	12.86	3.8700	145	17.81	3.8900	-	-4.95	[-5.84; -4.06]	33.4%	23.8%
Matsuyama 2023	10	2.90	2.8060	10	14,40	4.2700		-11.50	[-14.67; -8.33]	2.7%	13.3%
Fixed effect model	448			448			<b>b</b>		[-6.53; -5.48]		-
Random effects model							<b>⇔</b>	-6.87	[-8.62; -5.13]		84.0%
Heterogeneity: $I^2 = 89\%$ , $\tau^2 = 2.5770$ , p	< 0.01										
Fixed effect model	478			478			<b>♦</b>	-6.14	[-6.65; -5.62]	100.0%	_
Random effects model							<b>⇔</b>	-7.27	[-8.94; -5.60]		100.0%
Heterogeneity: $I^2 = 88\%$ , $\tau^2 = 2.8584$ , p	< 0.01										
Residual heterogeneity: $I^2 = 89\%$ , $p < 0$							-10 -5 0 5 10				

Supplementary Fig. 1. Changes in LMCT scores from baseline (dupilumab). The mean post-treatment differences in the LMCT scores at 3, 6, and 12 months of treatment [9,12,18]. Totals: numbers of participants per group. LMCT, Lund-Mackay computed tomography score; SD, standard deviation; MD, mean difference; CI, confidence interval.